The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Study design of a global molecular disease characterization initiative (MDCI) in oncology clinical trials.
 
David Downs
Honoraria - GlaxoSmithKline
Speakers' Bureau - GlaxoSmithKline
 
Rob Weker
Stock and Other Ownership Interests - Danaher; GlaxoSmithKline; Johnson & Johnson; Pfizer
Consulting or Advisory Role - GlaxoSmithKline; Incyte
Other Relationship - Canopy Collective; University of Pennsylvania
 
Melissa Lynne Johnson
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Axelia Oncology (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); EcoR1 Capital (Inst); Editas Medicine (Inst); Eisai (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); IDEAYA Biosciences (Inst); ITeos Therapeutics (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Oncorus (Inst); Regeneron (Inst); Ribon Therapeutics (Inst); Sanofi (Inst); Turning Point Therapeutics (Inst); WindMIL (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Adaptimmune (Inst); Amgen (Inst); Apexigen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Artios (Inst); AstraZeneca (Inst); Atreca (Inst); BeiGene (Inst); BerGenBio (Inst); BioAtla (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Carisma Therapeutics (Inst); Checkpoint Therapeutics (Inst); Corvus Pharmaceuticals (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dracen (Inst); Dynavax Technologies (Inst); Elicio Therapeutics (Inst); EMD Serono (Inst); Erasca, Inc (Inst); Exelixis (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Guardant Health (Inst); Harpoon (Inst); Helsinn Healthcare (Inst); Hengrui Pharmaceutical (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); IGM Biosciences (Inst); Immunocore (Inst); IMPAC Medical Systems (Inst); Incyte (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Kadmon (Inst); Kartos Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Merus (Inst); Mirati Therapeutics (Inst); NeoImmuneTech (Inst); Neovia Oncology (Inst); Novartis (Inst); Numab (Inst); Nuvalent, Inc. (Inst); OncoMed (Inst); Palleon Pharmaceuticals (Inst); Pfizer (Inst); PMV Pharma (Inst); Rain Therapeutics (Inst); RasCal (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Seven and Eight Biopharmaceuticals (Inst); Shattuck Labs (Inst); Silicon Therapeutics (Inst); Stem CentRx (Inst); Syndax (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TCR2 Therapeutics (Inst); Tempest Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Turning Point Therapeutics (Inst); University of Michigan (Inst); Vyriad (Inst); WindMIL (Inst); Y-mAbs Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech; Incyte; Merck; Pfizer; Sanofi
 
Adrian G. Sacher
Honoraria - Amgen; AstraZeneca; Genentech/Roche
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Genentech/Roche
Research Funding - AstraZeneca; Genentech/Roche
 
Marcus O. Butler
Honoraria - Bristol-Myers Squibb; Merck; Novartis; Roche
Consulting or Advisory Role - Adaptimmune; Adaptimmune; Bristol-Myers Squibb; EMD Serono; Genzyme; GlaxoSmithKline; GlaxoSmithKline; Immunocore; Immunovaccine; Instil Bio; Iovance Biotherapeutics; LaRoche Posay; Medison; Merck; Novartis; Pfizer; Sanofi; Sun Pharma
Research Funding - Merck; Takara Bio
Expert Testimony - Merck
 
Hassane M. Zarour
Consulting or Advisory Role - Checkmate Pharmaceuticals; ITeos Therapeutics; Vedanta Biosciences
Research Funding - Merck Sharp & Dohme (Inst); Tesaro (Inst)
 
Jeffrey S. Weber
Stock and Other Ownership Interests - Biond; Evaxion Biotech; Instil Bio; NexImmune; OncoC4
Honoraria - Amgen; AstraZeneca; Biond Biologics; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Genentech; GlaxoSmithKline; Idera; Incyte; Instil Bio; Jounce Therapeutics; Kirin Pharmaceuticals; Merck; Moderna Therapeutics; NexImmune; Novartis; OncoC4; Oncosec; Pfizer; Regeneron; Roche; Sellas Life Sciences; Takeda; Ultimovacs; WindMIL
Consulting or Advisory Role - Amgen; AstraZeneca; Biond Biologics; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Genentech; GlaxoSmithKline; Idera; Incyte; Instil Bio; Jounce Therapeutics; Kirin Pharmaceuticals; Merck; Moderna Therapeutics; NexImmune; Novartis; OncoC4; Oncosec; Pfizer; Protean Biodiagnostics; Roche; Sellas Life Sciences; Ultimovacs; WindMIL
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Merck (Inst); Moderna Therapeutics (Inst); NextCure (Inst); NextCure (Inst); Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - named on a patent for 41BB induced TIL by Moffitt Cancer Center; named on a patent from Biodesix for a PD-1 antibody biomarker; Named on a patent submitted by Moffitt Cancer Center for an IPILIMUMAB biomarker
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; Genentech; GlaxoSmithKline; Merck; Novartis; Roche
 
Edward B. Garon
Consulting or Advisory Role - ABL Bio; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Gilead Sciences; GlaxoSmithKline; Lilly; Merck; Natera; Novartis; Personalis; Sanofi/Regeneron; Shionogi; Xilio Therapeutics
Research Funding - ABL Bio (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dynavax Technologies (Inst); EMD Serono (Inst); Genentech (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Diagnosistic and therapeutic use of "Motif Neoepitopes" as defined by Cummings et al in Nature Cancer. (Inst)
 
David Paul Carbone
Employment - James Cancer Center
Honoraria - AstraZeneca; Bristol-Myers Squibb-Ono Pharmaceutical
Consulting or Advisory Role - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb Japan; Daiichi Sankyo; Eisai; EMD Serono; Flame Biosciences; Genentech/Roche; Geneplus; GlaxoSmithKline; Gritstone Bio; Intellisphere; Janssen; Johnson & Johnson/Janssen; Lilly; Merck; Mirati Therapeutics; Novocure; OncoCyte; Oncohost; Regeneron; Roche China; Sanofi; Seagen
Research Funding - Bristol-Myers Squibb
 
Ann Dokus
Employment - IQVIA
Stock and Other Ownership Interests - IQVIA; Pfizer
 
Jessica Taylor
Employment - IQVIA
Stock and Other Ownership Interests - IQVIA
Research Funding - IQVIA (Inst)
 
Arindam Dhar
Employment - GlaxoSmithKline; PRA Health Sciences (I); PurpleLab (I)
Stock and Other Ownership Interests - Bristol-Myers Squibb; GlaxoSmithKline; PRA Health Sciences (I); PurpleLab (I); Regeneron
 
Marilyn Metcalf
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Cristina Messina
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
John Yonchuk
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Kristin Blouch
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Anne-Marie Martin
Employment - GlaxoSmithKline; SwanBio Therapeutics (I)
Stock and Other Ownership Interests - GlaxoSmithKline; SwanBio Therapeutics (I)